Table 2

MRI signal and tumor characteristics of HCC target lesions at baseline and follow-up

Pat.

Dose

(mg)#

MRI-FU

Lesion

(no.)

Size

(mm)

T1

T2 fs

Necr.

[NT]/[TV] (%)

Sum

(mm)


1

-

baseline

liver

25

2

4

-

-

25

800

3 w.

(1)

30

4

4

<25

30

800

8 w.

30

2

5

<25

30

800

16 w.

34

2

5

<25

34


2

-

baseline

liver

160

2

3

+

<50

170

400

2 w.

(2)

165

4

5

<50

175

800

6 w.

160

4

3

<75

172

400

14 w.

155

2

3

>75

172


3

-

baseline

liver

35

2

4

-

-

35

800

2 w.

(4)

35

2

4

-

-

35

200

6 w.

35

2

4

-

-

35

200

12 w.

39

4

3

<25

39


4

-

baseline

liver

57

3

4

+

<25

57

800

4 w.

(1)

57

4

5

<25

57


5

-

baseline

liver

30

2

4

+

<25

30

800

2 w.

(1)

30

2

4

<25

30

800

6 w.

31

2

5

<25

31

400

13 w.

30

2

5

<25

30

400

20 w.

40

2

5

<25

40


6

-

baseline

liver

133

2

4

+

<25

133

800

3 w.

(1)

135

3

5

<25

135

800

7 w.

130

2

3

<25

130


7

-

baseline

liver

38

2

2

+

<25

70

800

2 w.

(3)

45

5

4

>75

80

-

8 w.

32

3

3

<50

66

400

16 w.

32

3

3

<25

71


8

-

baseline

adrenal

45

3

3

+

<25

144

800

3 w.

(3)

45

5

4

<25

144

400

8 w.

57

5

4

<25

156


9

-

baseline

liver

20

2

4

-

-

119

800

5 w.

(3)

22

4

5

>75

123

800

14 w.

20

4

5

>75

119

800

20 w.

20

2

4

>75

119


10

-

baseline

perit.

12

2

3

-

-

12

800

2 w.

(2)

12

3

5

+*

12

800

7 w.

6

3

3

+*

6

400

15 w.

0

-

-

-

-

0

400

23 w.

0

-

-

-

-

0


11

-

baseline

liver

10

2

4

-

-

19

800

3 w.

(2)

14

2

4

-

-

26

800

7 w.

17

2

4

-

-

31

800

15 w.

18

2

4

-

-

35

800

22 w.

21

2

4

-

-

38


12

-

baseline

adrenal

15

2

4

+

<25

50

800

4 w.

(2)

12

2

4

<50

42

800

12 w.

8

2

5

<50

36

200

19 w.

8

2

5

<50

38


13

-

baseline

liver

38

3

4

+

<25

38

400

3 w.

(1)

38

3

3

<25

38

-

7 w.

55

4

3

<25

55

200

15 w.

39

3

3

<50

39


14

-

baseline

liver

17

5

2

+

<25

70

800

2 w.

(2)

17

5

2

<25

70

800

5 w.

17

5

2

<50

70

200

15 w.

17

5

2

<50

70

400

23 w.

17

5

2

>75

70


15

-

baseline

bone

45

4

2

-

-

149

800

5 w.

(3)

55

5

4

>75

176

800

9 w.

45

4

5

>75

193

800

16 w.

44

4

4

>75

172

800

21 w.

45

5

4

>75

168

800

24 w.

50

5

3

>75

163

800

32 w.

60

4

3

>75

172


16

-

baseline

liver

52

4

2

+

<25

83

400

3 w.

(2)

52

4

2

<25

83

-

9 w.

52

3

2

<25

83


17

-

baseline

liver

51

1

4

+

<25

93

800

4 w.

(2)

57

4

5

>75

107


18

-

baseline

liver

120

1

4

+

<50

120

800

7 w.

(1)

130

1

4

<50

130


19

-

baseline

liver

151

1

4

+

<25

201

400

6 w.

(2)

155

4

2

<50

210

800

18 w.

165

5

5

>75

229


20

-

baseline

liver

15

3

3

-

-

15

400

2 w.

(1)

15

5

4

<50

15


21

-

baseline

liver

62

2

4

-

-

88

400

8 w.

(2)

75

4

5

<50

97

200

15 w.

75

4

5

<50

97

200

22 w.

81

3

3

<50

96

200

29 w.

98

5

5

<50

113


Abbreviations:

Pat.: patient number. #Daily dose at the time point of each MRI imaging study. MRI-FU: MRI at follow-up;

w.: week after therapy initiation. Lesion: location of representative analysed lesion and number of total lesions at this location. Size: size of the representative tumor lesion im mm. T1: T1-weighted image. T2fs: T2-weighted fat saturated image. Qualitative assessment of signal in relation to the signal of liver parenchyma (1 = markedly hypointense; 2 = slightly hypointense; 3 = isointense; 4 = slightly hyperintense; 5 = markedly hyperintense).

PV: portal vein; perit.: peritoneal. Gd: Gadolinium-enhancement at baseline and its evolution at follow-up

(↑ = increase; ↓ = decrease; ↔ = unchanged; (-) no necrosis detectable; (+) necrosis at baseline detectable). [NT]/[TV]% = percentage of necrosis volume to total tumor volume, expressed as a score with (--) no necrosis, <25%, <50%, <75%, or >75%. Sum (mm) = sum of the diameter of all detectable lesions at this location.

+* = the necrotic areas could not be reliably quantified.

Horger et al. BMC Cancer 2009 9:208   doi:10.1186/1471-2407-9-208

Open Data